viewIQ-AI Limited

IQ-AI Limited - "Gad Free" Imaging moves to Validation Testing

RNS Number : 6699D
IQ-AI Limited
30 October 2020


("IQ-AI" or the "Company")

 "Gad Free" Imaging Moves To Validation Testing

IQ-AI advances its contrast free imaging project to the next stage, validation testing. The validation stage includes subjecting the Artificial Intelligence (AI) model to a large and varied set of data, and statistically comparing the model's output to "ground truth", or actual, images acquired using contrast. The testing results will refine the model sufficiently to prepare it for the final stage - regulatory clearance.


One in three MRI scans use contrast to improve the diagnostic accuracy of the scan. In the US alone, that equates to approximately 10 million scans per year of which 40% are neuro scans. While the associated cost savings of contrast agent material alone is substantial, the potential impact to routine clinical practice is also significant. For instance, not having to inject contrast agents results in more efficient clinical workflows. Moreover, since the administration of contrast agent is not always performed properly and may result in lost scanner time or rescheduled scans, patient throughput and scanner utilisation may also increase. There are also costs associated with the power injectors themselves. Most importantly, a successful gad-free program will further reduce the potential risks associated with gadolinium retention in the body.


The patent application for "gad free" imaging, filed in October of 2018 with the United States Patent and Trademark Office, remains under review.


The Directors of the Company accept responsibility for the contents of this announcement.




For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797



ABOUT Imaging Biometrics, LLC

Imaging Biometrics®, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat disease with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent and automated software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Quick facts: IQ-AI Limited

Price: -

Market: LSE
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


StoneChecker still on track for FDA clearance and commercial roll out of...

Nick Stevens, chief executive of StoneChecker, which is part of the Flying Brands group (LON:FDBU) tells Proactive's Andrew Scott that despite a small delay in the US FDA clearance process, they're still looking at a commercial roll out in Q4 this year. Once approved, the group aims to...

on 23/7/18

3 min read